Navigation Links
Cardium's InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study
Date:12/16/2008

's patient temperature modulation business or market, that product modifications or launches will be successful or that the resulting products will be favorably received in the marketplace, that our products or proposed products will prove to be sufficiently safe and effective, that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive, that results or trends observed in one clinical study will be reproduced in subsequent studies, that third parties on whom we depend will behave as anticipated, or that necessary regulatory approvals will be obtained. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development, testing and marketing of therapeutic hypothermia devices and the conduct of human clinical trials, including the timing, costs and outcomes of such trials, whether our efforts to launch new devices and systems and expand our markets will be successful or completed within the time frames contemplated, our dependence upon proprietary technology, our ability to obtain necessary funding, regulatory approvals and qualifications, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2008 Cardium Therapeutics, Inc. All rights reserved.

For Terms of Use Privacy Policy, please visit '/>"/>

SOURCE Cardium Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
2. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
3. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
4. Cardium Announces InnerCools New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification
5. Cardium Announces FDA 510(K) Clearance of InnerCools RapidBlue(TM) Endovascular System
6. Cardiums InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... (PRWEB) April 23, 2015 ... refer to a series of genetic tests that ... fibrosis, Lou Gehrig's disease, Huntington's disease, and Alzheimer's ... the gene composition and interaction in diseased tissue/cells ... as well as the response to treatment, such ...
(Date:4/23/2015)... Proove Biosciences , a ... excited to announce the launch of Proove ... assesses 62 genetic variations to predict good versus ... prescribed non-opioid pain medications, namely ibuprofen (brand name ... name Xanax) and acetaminophen (brand name Tylenol). ...
(Date:4/23/2015)... CA (PRWEB) April 23, 2015 Delpor, ... today announced that the United States Patent and Trademark ... Company’s NANOPOR™ technology. US Pat. No. ... Delpor’s microfabricated drug delivery device for the ... proprietary NANOPOR™ technology for the sustained (zero-order) release of ...
(Date:4/22/2015)... Wilmington, Del. (PRWEB) April 22, 2015 ... acquire Taxon Biosciences, Inc., a leading microbiome discovery ... capabilities and unparalleled market access in both seed ... solutions for agriculture customers globally. , “In ... Health and Industrial Biosciences segments sold more than ...
Breaking Biology Technology:Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 2Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 3Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 2Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 3Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3DuPont Acquires Taxon Biosciences, Inc. 2DuPont Acquires Taxon Biosciences, Inc. 3DuPont Acquires Taxon Biosciences, Inc. 4
... TELK ) reported a net loss of $13.6 million, or ... compared with a net loss of,$14.3 million, or $0.27 per ... loss for the second quarter ended June 30, 2008, includes,a ... reflected in interest and other income (expense)., For the ...
... NEW YORK, Aug. 11 Immtech Pharmaceuticals,Inc. (Amex: ... ended June,30, 2008., For the three months ended ... for the three months ended June 30, 2007. The ... testing,agreement. Loss from operations for the three months ended ...
... GSK anticipates delivery of at least half of ... Aug. 11 GlaxoSmithKline (NYSE:,GSK) today announced that ... and FLUARIX(R) [Influenza Virus Vaccine] to U.S. customers,for ... Drug Administration,s,(FDA) Center for Biologics Evaluation and Research ...
Cached Biology Technology:Telik Announces Financial Results For 2008 Second Quarter 2Telik Announces Financial Results For 2008 Second Quarter 3Telik Announces Financial Results For 2008 Second Quarter 4Immtech Reports Fiscal First Quarter 2009 Results 2Immtech Reports Fiscal First Quarter 2009 Results 3GSK Begins Shipments of Fluarix(R) and FluLaval(R) to U.S. Customers for 2008-2009 Influenza Season 2GSK Begins Shipments of Fluarix(R) and FluLaval(R) to U.S. Customers for 2008-2009 Influenza Season 3GSK Begins Shipments of Fluarix(R) and FluLaval(R) to U.S. Customers for 2008-2009 Influenza Season 4
(Date:4/2/2015)... April 2, 2015 Fingerprint Cards ... sensor FPC1025 from the distributor World Peace Industrial Group ... Q2 2015 although the major part of the shipments ... be used by smartphone manufacturers in China ... included in the communicated revenue guidance of + 1 000 ...
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has ... Market in Automotive Sector 2014-2018" report to their ... Recognition market in Automotive Sector to grow at a ... Gesture recognition is the ability of a device to ... Gesture recognition technology can be 2D-based or 3D-based. It ...
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... Center researchers reveals how a well-known tumor suppressor gene may ... published online today in Oncogene , focus on the ... who have hereditary breast and/or ovarian cancers, according to senior ... of Human Science at the School of Nursing & Health ...
... dementia and while some risks are known, for example ... clear. New research published in BioMed Central,s open access ... hospitalization and treatment in the intensive care unit (ICU) ... such as delirium, or acute dialysis are all independently ...
... small-scale polar storms could make a big difference to climate ... Anglia and the University of Massachusetts. Difficult-to-forecast polar ... are missing in most climate models. Research published ... could paint a different picture of climate change in years ...
Cached Biology News:Study uncovers mechanism used by BRCA1 to suppress tumors 2Worries about dementia how hospitalization affects the elderly 2'Missing' polar weather systems could impact climate predictions 2
... The lyophilization stabilizer is designed to ... and for long-term storage. There ... ingredients. It is a convenient ... 7.2, and is superior to other ...
... The CERTOMAT IS, a true benchtop incubator-shaker, has ... Having a footprint of 540 x 680 ... large incubation chamber (370 x 505 x 510mm). ... the CERTOMAT IS is ideal for shaking applications ...
... TC-3000 is one of the smallest thermal cyclers ... choice of either the 0.5ml (20 samples) or ... , Fast heating and cooling rate of ... and high performance Fast track programming with ...
... StabilZyme HRP Conjugate Stabilizer is an aqueous ... and other non-toxic stabilizing chemicals in a ... 6.7. This product contains a ... 20 ppm Proclin 300 (Rohm and Haas ...
Biology Products: